Financial statements Neomedic
Balance sheet data of NEOMEDIC
|
Year
|
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
|---|---|---|---|---|---|---|
| Total assets | 226 406 711,22 | 256 062 299,89 | 263 719 120,60 | 261 050 739,08 | 258 458 547,21 | 247 285 691,72 |
| A. Fixed assets | 215 550 913,49 | 251 891 510,76 | 252 837 997,39 | 254 237 718,36 | 254 602 941,36 | 239 417 601,31 |
| B. Current assets | 10 855 797,73 | 4 170 789,13 | 10 881 123,21 | 6 813 020,72 | 3 855 605,85 | 7 868 090,41 |
| C. Share capital contributions (basic funds) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| D. Own shares (stocks) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| Total liabilities | 226 406 711,22 | 256 062 299,89 | 263 719 120,60 | 261 050 739,08 | 258 458 547,21 | 247 285 691,72 |
| A. Equity | 205 369 769,20 | 216 346 717,74 | 223 837 814,39 | 220 977 835,48 | 217 648 516,11 | 218 072 132,00 |
| B. Liabilities and provisions for liabilities | 21 036 942,02 | 39 715 582,15 | 39 881 306,21 | 40 072 903,60 | 40 810 031,10 | 29 213 559,72 |
| I. Long-term liabilities | 10 630 163,29 | 38 657 855,59 | 38 597 199,89 | 38 838 556,30 | 38 804 844,03 | 203 526,79 |
| II. Short-term liabilities | 9 665 869,09 | 926 883,50 | 994 592,17 | 721 190,85 | 1 885 473,21 | 28 893 085,50 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.